Sanjiv Chopra, MD: Treatments for NAFLD on the Way

May 14, 2022
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Dr. Chopra said an FDA-approved treatment for NAFLD could come in the next 6 months.

The long pursuit of a US Food and Drug Administration (FDA) approved treatment for non-alcoholic fatty liver disease (NAFLD).

Despite no currently approved therapies for the disease, there are currently more than 400 clinical trials involving NALFD in some compacity, at least 1 stakeholder is confident there will be an approved treatment in the next calendar year.

In an interview with HCPLive®, Sanjiv Chopra, MD, Professor of Medicine, Harvard Medical School, said he hopes a treatment for NAFLD will finally be approved in as early as 6 months from now.

And while it can be difficult to predict how the US Food and Drug Administration might react, Chopra is confident they will approve a treatment for NAFLD.

“The FDA has gotten quicker and more efficient at approving drugs,” Chopra said. “I think we will see a bunch of these drugs approved in the next 6 months.”

Chopra said even with an FDA approval, care might not be transformed overnight.

“The challenge will be are the insurance companies going to pay for it and what is the cost going to be,” he said. For some of these drugs the cost is $1,200 or $1,500 a month. That’s a lot of money and many of the people who most need it will be the ones least likely to afford it.”